Click to view the programme
ON-DEMAND 30-MINUTE WEBINARS
Available from 10:00 CET from 28 January to 11 February.
Scroll down for more details on each lecture.
LIVE ROUNDTABLE DISCUSSION
Friday 11 February 2022, 18:00-19:30 CET
AGENDA
18:00 Introduction by David Rice
18:05 Q&A with Tuula Palotie, University of Helsinki (Finland)
18:20 Q&A with Marie Marklund, Umeå University Clinic (Sweden)
18:35 Q&A with Giulio Alessandri-Bonetti, University of Bologna (Italy))
18:50 Roundtable discussion
19:30 Closing message by David Rice
Obstructive sleep apnoea and its association with asthma, cardiovascular disease, diabetes and covid-19
Professor Tuula Palotie
Associate professor at the Department of Oral and Maxillofacial Diseases, University of Helsinki, Finland.
Speaker Bio
Tuula Palotie received her DDS in 1991, PhD in 1995, Specialist in Orthodontics in 1999 and Docent 1999 from the University of Helsinki, Finland. She is an Associate professor at the Department of Oral and Maxillofacial Diseases, Helsinki University Hospital and Orthodontics, Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Finland. Her main current scientific interests are obstructive sleep apnoea appliances, genetics of sleep apnoea, juvenile rheumatoid arthritis and orthognathic surgery
Learning Objectives
- TOSA treatment improves asthma symptoms.
OSA is an independent risk factor for coronary heart disease, type 2 diabetes and diabetic kidney disease.
Among COVID-19 positive patients with moderate or severe OSA, OSA is associated with higher risk for hospitalization.
Abstract
Obstructive sleep apnoea (OSA) is a severe sleep disorder affecting approximately 25 per cent of the population. OSA is characterized by repetitive episodes of nocturnal breathing cessation causing mild to severe OSA. These conditions may lead to serious comorbidities. OSA is influenced by multiple risk factors such as obesity, male gender, family history of OSA, increased age and problems in upper airway flow or jaw anatomy.
OSA therapy includes conservative treatment, continuous positive airway pressure, mandibular advancement splint (MAS) therapy and surgery.
MAS therapy significantly decreases apnoeas and hypopnoeas, and its long-term use is associated with an improvement in respiratory and asthma symptoms.
Our longitudinal population-based study with up to 25-year follow-up data on 36,963 individuals from three population-based cohorts: the FINRISK study, the Health 2000 Cohort Study and the Botnia Study showed that OSA is an independent risk factor for coronary heart disease, type 2 diabetes and diabetic kidney disease.
A large-scale genome-wide association study of OSA using the FinnGen data (217 ,955 individuals) with 16,761 OSA patients identified using nationwide health registrations supported the causal link between obesity and OSA, and the genetic basis between OSA and comorbidities such as hypertension, type 2 diabetes, coronary heart disease, stroke, depression, hypothyroidism and asthma.
According to previous results contracting COVID-19 was the same for patients with OSA and those without OSA. In contrast, among COVID-19 positive patients with moderate or severe OSA, OSA was associated with higher risk for hospitalization.
Long term effects and side-effects from oral appliance therapy
Professor Marie Marklund
Senior Assistant Professor at the Department of Odontology. Umea University, Sweden
Speaker Bio
Marie Marklund, DDS, PhD works at the University Clinic in Umeå, Sweden. Her interest in snoring and sleep apnoea started 37 years ago during a course in nitrous oxide sedation, when she considered the concept to test an activator on her snoring husband. The treatment was very successful and became the start of a long collaboration with the Pulmonary Department at Umeå University with research about treatment effects, side-effects, cardiovascular effects and longer term outcomes of oral appliances (OA). She has collaborated with Antwerp University Hospital, Belgium and has lectured extensively worldwide, including keynote lectures, and published many articles about OA treatment for obstructive sleep apnoea, including book chapters and two Task Forces for the European Respiratory Society. She is a board member of the Swedish Sleep Research and Sleep Medicine Society and has been a board member of the European Academy of Dental Sleep Medicine and worked in the programme committee for the American Academy of Dental Sleep Medicine. Marie Marklund is the recipient of the 2019 Lifetime Achievement Award from the Interdisciplinary Belgian Dental Surgery Sleep Medicine Academy, the 2018 Honorary Member Award and the 2008 Pierre Robin Award from the American Academy of Dental Sleep Medicine, the 2014 Meier-Ewert Award from the Deutsche Gesellschaft Zahnärztliche Schlafmedizin, and the 2008 Traffic Award from a Swedish transport company.
Learning Objectives
- The purpose of the presentation to provide the latest knowledge about the long-term outcomes of MAD therapy in patients with OSA.
Abstract
In Mandibular advancement devices (MADs) have the highest level of evidence among non-continuous positive airway pressure therapies in the short term perspective for patients with obstructive sleep apnoea (OSA). The longer term outcomes have been less studied. This presentation will overview the latest indications for MAD therapy and describe what is known about longer term outcomes, in terms of adherence, effects and side-effects.
The longer term outcomes of MAD therapy will be influenced by a number of factors that might happen to the patient, except for an increase in age, they may change their weight and suffer from various comorbidities. Effects from MAD therapy have mainly been described as the results of the apnoea-hypopnoea index in patients with continuing OSA. Some studies also describe the longer term effectiveness, which is important, since patients may switch to another therapy, usually positive airway pressure, or stop treatment of various reasons. Some longer term results also exist on the effects on symptoms and comorbidities, mainly hypertension.
Bite changes constitute the most important long-term side-effect. All patients risk a reduction in mandibular advancement when the occlusion continuously might change towards a Class III malocclusion. It is therefore important to follow-up the degree of mandibular advancement with the appliance, and adjust if necessary. But, the bite change might also be beneficial for patients with a Class II malocclusion.
In summary, it is important to control the patient regarding symptoms, comorbidities and bite changes in the longer term perspective, in order to maintain effective OSA treatment.
In Mandibular advancement devices (MADs) have the highest level of evidence among non-continuous positive airway pressure therapies in the short term perspective for patients with obstructive sleep apnoea (OSA). The longer term outcomes have been less studied. This presentation will overview the latest indications for MAD therapy and describe what is known about longer term outcomes, in terms of adherence, effects and side-effects. The longer term outcomes of MAD therapy will be influenced by a number of factors that might happen to the patient, except for an increase in age, they may change their weight and suffer from various comorbidities. Effects from MAD therapy have mainly been described as the results of the apnoea-hypopnoea index in patients with continuing OSA. Some studies also describe the longer term effectiveness, which is important, since patients may switch to another therapy, usually positive airway pressure, or stop treatment of various reasons. Some longer term results also exist on the effects on symptoms and comorbidities, mainly hypertension. Bite changes constitute the most important long-term side-effect. All patients risk a reduction in mandibular advancement when the occlusion continuously might change towards a Class III malocclusion. It is therefore important to follow-up the degree of mandibular advancement with the appliance, and adjust if necessary. But, the bite change might also be beneficial for patients with a Class II malocclusion. In summary, it is important to control the patient regarding symptoms, comorbidities and bite changes in the longer term perspective, in order to maintain effective OSA treatment.
Obstructive sleep apnoea, an opportunity for the clinician
Professor Giulio Alessandri-Bonetti
Associate Professor and Chair of the Department of Orthodontics and Sleep dentistry at the University of Bologna, Italy
Speaker Bio
Professor Giulio Alessandri-Bonetti graduated in Medical Sciences (MD) followed by a postgraduate degree in Dental Sciences (DDS) at the University of Bologna. He received a postgraduate in orthodontics at the University of Ferrara. He is Associate Professor and Chair of the Department of Orthodontics and Sleep dentistry at the University of Bologna; director of Master in Dental Sleep Medicine. He has authored or co-authored more than 120 research papers and book-chapters. In 2012 he received the David L. Turpin Award for Evidence-Based Research from the American Journal of Orthodontics and Dentofacial Orthopedics. He is currently member of the Italian Society of Orthodontics (SIDO), the European Orthodontic Society, the American Association of Orthodontists, the American Academy of Dental Sleep Medicine , the European Sleep Research Society, the Italian Association of Sleep Medicine (AIMS) and the Italian Society of Dental Sleep Medicine (SIMSO).
Learning Objectives
- The lecture aims to provide the clinician with knowledge about the definition, diagnosis and identification of patients potentially affected by OSA.
Abstract
The lecture will highlight the importance of the clinician’s role in sleep apnoea (OSA) patients; on the one hand, that of suspecting the pathology and undertaking screening whilst on the other, in selected cases, to intervene with the use of a mandibular advancement device.
To carry out this dual task, a comprehensive knowledge of OSA pathology is required.
The factors of suspicion will be illustrated, highlighting how the definitive diagnosis of OSA is not of dental relevance.
The lecture will highlight the importance of the clinician’s role in sleep apnoea (OSA) patients; on the one hand, that of suspecting the pathology and undertaking screening whilst on the other, in selected cases, to intervene with the use of a mandibular advancement device. To carry out this dual task, a comprehensive knowledge of OSA pathology is required. The factors of suspicion will be illustrated, highlighting how the definitive diagnosis of OSA is not of dental relevance.
Chairperson
David Rice
Professor and Head of Orthodontics at the University of Helsinki, Finland
Speaker Bio
David Rice is Professor and Head of Orthodontics at the University of Helsinki and Helsinki University Hospital. Since 2021 he has also been Dean of Dentistry. He specialised in orthodontics in the United Kingdom before completing his PhD in craniofacial developmental biology in Finland. From 2014 to 2019 he was Director of the Finnish National Doctoral Programme in Oral Sciences. Since 2010, Professor Rice has been Editor of the European Journal of Orthodontics. As Editor, he is intimately involved in developing and improving the standards of all aspects of orthodontic research with the ultimate goal of improving patient care that is based on quality evidence. .
REGISTRATION FEES
Registration entitles you to access the 3 on-demand webinars from 28 January to 11 February, and the live roundtable discussion on 11 February, 18:00-19:30 CET.
Registration fees are inclusive of 20% VAT and non-refundable. Payment must be made electronically by credit/debit card.
To become a member of the European Orthodontic Society and benefit from the discounted fees, click here.
| CATEGORY | FEE |
| EOS Member and Life Member | £20.00 |
| EOS Postgraduate Student/Trainee | £10.00 |
| Non-member | £90.00 |
| Postgraduate Student/Trainee (Non-member) | £45.00 |
Contact us
+44(0)2078085623
EOSevents@tfilodestar.comFollow eos and join in the conversation!
#EOSwebinar #orthodontics